Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ISA 51 VG Clear all
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions
gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

NCT00273910
View directory record Official record
Conditions
High-Risk Melanoma
Interventions
gp100:209-217 (210M), Montanide ISA-51, Imiquimod
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00109811
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

NCT00071981
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, sargramostim, tetanus peptide melanoma vaccine
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
65
States / cities
Palo Alto, California • Stanford, California • Lewes, Delaware + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

NCT00089063
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 28, 2026, 4:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01312389
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 28, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

NCT00428077
View directory record Official record
Conditions
Leukemia
Interventions
bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction
Biological · Genetic
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

NCT01842139
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

NCT01748747
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis, Gag:267-274 peptide vaccine, resiquimod
Drug · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

NCT01176461
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1, NY-ESO-1, gp100:209-217(210M), gp100:280-288(288V), Montanide ISA 51 VG, BMS-936558
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study

NCT02229084
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
P10s-PADRE/ MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Docetaxel
Biological · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 4:33 AM EDT
Not yet recruiting Phase 2 Interventional

Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of Triple Negative Breast Cancer Patients

NCT02938442
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Neoplasms
Interventions
P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Paclitaxel
Biological · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 28, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

NCT00004918
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
Interventions
PR1 leukemia peptide vaccine, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 28, 2026, 4:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02455557
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Other · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 4:33 AM EDT
Active, not recruiting Phase 3 Interventional

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma
Interventions
IO102-IO103, Pembrolizumab
Drug
Lead sponsor
IO Biotech
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Orange City, Florida • Orlando, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 28, 2026, 4:33 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccination With Tetanus and KLH to Assess Immune Responses.

NCT00000105
View directory record Official record
Conditions
Cancer
Interventions
Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51, Tetanus toxoid
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 28, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

NCT02665364
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
IFNα-Kinoid, Placebo, ISA 51 VG
Biological · Other
Lead sponsor
Neovacs
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 28, 2026, 4:33 AM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

NCT05280314
View directory record Official record
Conditions
Melanoma, Squamous Cell Carcinoma of Head and Neck
Interventions
IO102-IO103, Pembrolizumab KEYTRUDA®
Drug
Lead sponsor
IO Biotech
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 28, 2026, 4:33 AM EDT